Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2).
Alexandra N GriessbachFrédérique ChammartinIrene A AbelaPatrizia AmicoMarcel P StoeckleAnna L EichenbergerBarbara HasseDominique L BraunMacé M SchuurmansThomas F MüllerMichael TammAnnette AudigéNicolas J MuellerAndri RauchHuldrych F GünthardMichael T KollerAlexandra TrkolaSelina EppAlain AmstutzChristof M SchönenbergerAla Taji HeraviKatharina KusejkoHeiner C BucherMatthias BrielBenjamin Speichnull nullPublished in: Open forum infectious diseases (2023)
Extension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response of the third dose of Moderna mRNA-1273 vaccine (95.3% [95% confidence interval {CI}, 91.9%-98.7%]) compared to Pfizer-BioNTech BNT162b2 vaccine (98.1% [95% CI, 95.9%-100.0%]) in individuals with different levels of immunosuppression (difference, -2.8% [95% CI, -6.8% to 1.3%]).